Charles River Laboratories International, Inc. (CRL)
NYSE · Common stock · Services-Commercial Physical & Biological Research
As of Oct 21, 12:04 PM ET15 min delayedAbout 15 minutes behind the market. Every member plan is real time.
Follow CRL in real time
Real-time quotes, Pro Charting, the scanner and the alert feed on CRL and every other US listing.
Start 5 days freeTry Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.
CRL at a glance
Key statistics
$15.06B
Market capitalization
- Previous close
- $315.45
- Open
- $314.63
- Day range
- $314.63 – $338.79
- Volume
- 702.8K
- Average volume (30 sessions)
- 989.7K
- Shares outstanding
- 47.74M
- Earnings per share
- $(5.00)
- Price / book
- 5.3
- Price / sales
- 3.8
- Beta (1 year, vs SPY)
- 1.25
Where the price sits in its year
52-week range
100% of the range
- Below the 52-week high
- -0.1%
- Above the 52-week low
- +131.5%
Completed sessions through Oct 20, 2026
Technical snapshot
Above its 50-day and 200-day averages
- 20-day average
- $298.39+5.7%
- 50-day average
- $290.30+8.7%
- 200-day average
- $216.16+45.9%
Between the conventional 30 and 70 bands.
+5.5%
1 week
+13.1%
1 month
+44.2%
3 months
+58.1%
Year to date
+76.7%
1 year
Price change over each window, from completed sessions. Past performance does not indicate future results.
Every plan: MACD, ATR, the 20- and 50-day ranges, five-year and all-history extremes and the full indicator set, live on Pro Charting.The member platform, in real time
What members do with CRL
CRL on Pro Charting
Every intraday interval in real time, the drawing kit and the full set of technical studies on CRL.
See the plans →
Every planScreen names like CRL
The real-time scanner: price, volume, technical, fundamental and chart-pattern filters across the whole US market.
See the plans →
Analysis Tools OnlySet a price line on CRL
Put CRL on your watchlist, draw the levels you care about, and My Dashboard tracks where it trades against them.
See the plans →
Stock Alerts + ToolsOpen alerts on CRL
See whether there is an open premium alert on CRL, with its entry, stop and exit, each one reviewed by an analyst before it is sent.
See the plans →
From the public news wire
CRL headlines
- Global Synthetic Antibody Library Market Report 2026: Size and Forecast to 2030 | Capitalize on 12% CAGR and AI Design with Charles River, Twist Bioscience, GenScript and AbCellera
GlobeNewswire Inc. · Oct 12, 2026
- Pharmaceutical Impurity Synthesis and Isolation Services Report: Capitalize on a $2.1 Billion Market by 2030 as Tariffs and 8.9% Isolation Growth Reshape Competition Across Eurofins, WuXi AppTec, Cambrex and Charles River
GlobeNewswire Inc. · Sep 29, 2026
- Animal Testing and Non-Animal Alternative Testing Market Outlook 2025-2035 - Featuring Profiles of Charles River Laboratories, Labcorp, and Eurofins Scientific
GlobeNewswire Inc. · Aug 27, 2026
- Charles River Labs Breaks The Mold, Announces Bold Divestiture Plans
Benzinga · Feb 25, 2026
- Charles River Beat Expectations But Why Is The Stock Falling?
Benzinga · Nov 5, 2025
- Charles River Sees Limited Impact From NIH Cuts, Tariffs, Drug Pricing
Benzinga · Aug 6, 2025
- What's Going On With Charles River, Certara, Simulations Plus Stocks On Friday?
Benzinga · Apr 11, 2025
SEC Form 4, most recent first
Insider filings
Parisotto Shannon M
−981
CEVP, Disc & Safety Assessment · Option exercise
· Oct 5, 2026
Parisotto Shannon M
−981
CEVP, Disc & Safety Assessment · Open-market sale
$302.58K · Oct 5, 2026
Parisotto Shannon M
+981
CEVP, Disc & Safety Assessment · Option exercise
$204.48K · Oct 5, 2026
Coleman Glenn
+10
EVP & Chief Financial Officer · Open-market purchase
$2.97K · Sep 30, 2026
FOSTER JAMES C
+12.4K
Director · Option exercise
$2.59M · Aug 25, 2026
FOSTER JAMES C
−12.4K
Director · Option exercise
· Aug 25, 2026
FOSTER JAMES C
+21.1K
Director · Option exercise
$4.10M · Aug 25, 2026
FOSTER JAMES C
−21.1K
Director · Option exercise
· Aug 25, 2026
About Charles River Laboratories International, Inc.
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provide in vitro (nonanimal) testing products, biologics testing services, and avian vaccine services.
- Exchange
- NYSE
- Security
- Common stock
- Industry
- Services-Commercial Physical & Biological Research
- Headquarters
- Wilmington, MA
- Employees
- 19,700
- Listed since
- Jun 23, 2000
- Website
- criver.com
Pick the desk that fits how you trade
Analysis Tools Only for the real-time scanner, Pro Charting and the research desk. Stock Alerts + Tools for the human-reviewed alert feed. Premium Membership for both, at one price.
Try Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.
Other plans from $39 a month. Pay by card, Apple Pay, Google Pay, Link, Cash App Pay or Amazon Pay through Stripe.